Treatment with IV donanemab in early-stage Alzheimer’s disease demonstrated sustained clinical benefits for up to 3 years, with early initiation responsible for better outcomes, data from a long-term ...

This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Compounding Wealth Dividend growth investing is a time-tested strategy that combines the stability of regular income with the ...

On Friday, August 15, the stock market had a mixed day. The S&P 500 fell 0.29% after reaching a record high earlier. The Nasdaq Composite dropped by 0.40%.

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.